NCT03600350 2025-05-09
pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
University of Wisconsin, Madison
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT01341652 2021-01-20
Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT00488982 2019-11-20
Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)
University of California, San Francisco
Phase 2 Completed
NCT00450463 2018-11-29
Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00400517 2018-08-28
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
The Cleveland Clinic
Phase 2 Completed
NCT00477087 2017-11-29
Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer
Stanford University
Phase 2 Terminated
NCT00678054 2017-08-23
Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)
University of California, San Francisco
Phase 2 Completed
NCT00447473 2016-03-17
Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT00448409 2016-03-17
Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00450008 2016-03-17
Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT01530984 2015-10-05
Ipilimumab and GMCSF Immunotherapy for Prostate Cancer
University of California, San Francisco
Phase 2 Withdrawn